Home > Resources > Whitepapers > National Strategy for Biotechnology

National Strategy for Biotechnology

This document presents the Government’s strategy for biotechnology. The strategy has its origin in the Government’s white paper on research, Climate for Research, (Report No. 30 (2008-2009) to the Storting) which states that a balanced strategy for basic research, industry-oriented research, innovation activity and commercialisation in the field of biotechnology is to be developed.

Spotlight

CHIMA

The Canadian Health Information Management Association (CHIMA) represents approximately 5,000 Health Information Management (HIM®) professionals across Canada and is the certifying body and national association that represents leadership and excellence in health information management. CHIMA supports continuing education and professional practice of HIM professionals, develops strategic partnerships to advance the development and integration of electronic HIM, and advocates for and strengthens the HIM role in health care settings across the continuum of care.

OTHER WHITEPAPERS

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Accelerating Global Access to Gene Therapies: Case Studies from Lowand Middle-Income Countries

whitePaper | October 18, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result

Mainstreaming Cell & Gene Therapies

whitePaper | October 27, 2022

The cell and gene therapy (CGT) market is rapidly transitioning from ultra-niche cutting-edge science to approved and available therapies that can address previously intractable and often devastating diseases.

New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.